Latest:
Overview of Therapy for mCRPC: PARP Inhibitors
A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David Miller, MD
Obstetrics and Gynecology - Gyn Oncology
Latest:
Endometrial Cancer Today: Defining the Persistent Unmet Needs in Advanced and Recurrent Disease
Panelists discuss how advanced/recurrent endometrial cancer has remained a high unmet need due to years of minimal survival gains with carboplatin/paclitaxel until immunotherapy began shifting outcomes.
Vanderbilt-Ingram Cancer Center
Latest:
VIGH, VICC Establish Cancer Research Program in Zambia
Vanderbilt University Medical Center and the University of Zambia are partnering on a program to develop a cadre of researchers and educators to lead cancer epidemiology research and training in Zambia and to encourage U.S.-based researchers to engage in cancer research in low- and middle-income countries.
Amit Mahipal, MD
Latest:
Efficacy vs Toxicity With Immunotherapy
Panelists discuss how dual checkpoint inhibitors demonstrate significantly higher immune-related adverse event rates (nearly 30% grade 3-4) compared with atezolizumab-bevacizumab, but this increased toxicity is accompanied by meaningfully improved response rates, and the addition of anti-CTLA4 therapy roughly doubles response rates compared with anti-PD1 monotherapy in HCC.
Annie Deck-Miller
Latest:
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma
Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.
Vikas Mehta, MD, MPH, FACS
Latest:
BRONx-CAN Program Aims to Deliver the Best Cancer Treatments Early
Montefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.
Priya Rastogi, MD
Latest:
MonarchE: Primary Overall Survival Results Of Adjuvant Abemaciclib Plus Endocrine Therapy For HR+, HER2-, High-Risk Early Breast Cancer
Priya Rastogi, MD discusses MonarchE: primary overall survival results of adjuvant Abemaciclib plus Endocrine therapy For HR+, HER2-, high-risk early breast cancer.